Adicet Bio, Inc. (ACET)
Market Cap | 90.39M |
Revenue (ttm) | n/a |
Net Income (ttm) | -139.79M |
Shares Out | 82.17M |
EPS (ttm) | -2.94 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,173,921 |
Open | 1.160 |
Previous Close | 1.150 |
Day's Range | 1.090 - 1.160 |
52-Week Range | 1.090 - 3.770 |
Beta | 1.73 |
Analysts | Strong Buy |
Price Target | 15.17 (+1,279.09%) |
Earnings Date | Aug 7, 2024 |
About ACET
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Th... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ACET stock is "Strong Buy." The 12-month stock price forecast is $15.17, which is an increase of 1,279.09% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/p/a/press2-2503177.jpg)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
![](https://cdn.snapi.dev/images/v1/g/v/press16-2492405.jpg)
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
![](https://cdn.snapi.dev/images/v1/e/a/press11-2463246.jpg)
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
![](https://cdn.snapi.dev/images/v1/x/d/press17-2451180.jpg)
Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
![](https://cdn.snapi.dev/images/v1/2/l/press8-2430627.jpg)
Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
![](https://cdn.snapi.dev/images/v1/a/o/press19-2429716.jpg)
Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
![](https://cdn.snapi.dev/images/v1/n/w/press18-2414218.jpg)
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
![](https://cdn.snapi.dev/images/v1/k/u/press9-2401465.jpg)
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
![](https://cdn.snapi.dev/images/v1/s/2/press6-2384228.jpg)
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
![](https://cdn.snapi.dev/images/v1/t/a/conf13-2360576.jpg)
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
![](https://cdn.snapi.dev/images/v1/y/n/press12-2331822.jpg)
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
![](https://cdn.snapi.dev/images/v1/c/x/conf12-2317424.jpg)
Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
![](https://cdn.snapi.dev/images/v1/j/q/press16-2260805.jpg)
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
![](https://cdn.snapi.dev/images/v1/v/e/press2-2245540.jpg)
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
![](https://cdn.snapi.dev/images/v1/h/s/press5-2239559.jpg)
Adicet Bio, Inc. Announces Pricing of Public Offering
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies fo...
![](https://cdn.snapi.dev/images/v1/c/b/press2-2239211.jpg)
Adicet Bio, Inc. Announces Proposed Public Offering
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies fo...
![](https://cdn.snapi.dev/images/v1/g/y/press6-2216081.jpg)
Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer an...
![](https://cdn.snapi.dev/images/v1/j/d/conf9-2215440.jpg)
Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, t...
![](https://cdn.snapi.dev/images/v1/b/z/press6-2190423.jpg)
Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, t...
![](https://cdn.snapi.dev/images/v1/4/j/press10-2181750.jpg)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Adicet Bio, Inc. (NASDAQ: ACET)
NEW YORK , Dec. 4, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Adicet Bio, Inc. (NASDAQ: ACET) on behalf of the company's shareholders. The investigation seeks to d...
![](https://cdn.snapi.dev/images/v1/0/t/press2-2148184.jpg)
Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, t...
![](https://cdn.snapi.dev/images/v1/m/3/conf19-2143531.jpg)
Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, t...
![](https://cdn.snapi.dev/images/v1/z/z/press16-2136341.jpg)
Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, t...
![](https://cdn.snapi.dev/images/v1/h/l/press2-2089936.jpg)
Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, t...
![](https://cdn.snapi.dev/images/v1/q/a/conf5-2079795.jpg)
Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, t...